-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in HUTCHMED (China) Limited (NASDAQ:HCM) Drops By 18.9%
Short Interest in HUTCHMED (China) Limited (NASDAQ:HCM) Drops By 18.9%
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 1,760,000 shares, a decrease of 18.9% from the August 31st total of 2,170,000 shares. Based on an average daily volume of 350,900 shares, the short-interest ratio is presently 5.0 days.
Wall Street Analyst Weigh In
HCM has been the topic of a number of recent research reports. StockNews.com upgraded shares of HUTCHMED from a "sell" rating to a "hold" rating in a research note on Monday, August 1st. The Goldman Sachs Group boosted their price objective on HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 9th.
Get HUTCHMED alerts:HUTCHMED Stock Performance
HCM traded up $0.23 on Friday, reaching $8.86. The company's stock had a trading volume of 444,340 shares, compared to its average volume of 449,485. The stock has a 50 day moving average of $12.27 and a two-hundred day moving average of $13.25. HUTCHMED has a fifty-two week low of $8.37 and a fifty-two week high of $36.81.
Institutional Investors Weigh In On HUTCHMED
Several large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of HUTCHMED by 5.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,767 shares of the company's stock valued at $317,000 after acquiring an additional 892 shares during the period. Cubist Systematic Strategies LLC raised its stake in shares of HUTCHMED by 4.5% during the second quarter. Cubist Systematic Strategies LLC now owns 22,273 shares of the company's stock worth $282,000 after purchasing an additional 950 shares during the last quarter. Citigroup Inc. raised its stake in shares of HUTCHMED by 4.6% during the fourth quarter. Citigroup Inc. now owns 35,237 shares of the company's stock worth $1,236,000 after purchasing an additional 1,565 shares during the last quarter. Baillie Gifford & Co. raised its stake in shares of HUTCHMED by 0.5% during the first quarter. Baillie Gifford & Co. now owns 365,792 shares of the company's stock worth $6,921,000 after purchasing an additional 1,724 shares during the last quarter. Finally, Asset Management One Co. Ltd. raised its stake in shares of HUTCHMED by 10.9% during the second quarter. Asset Management One Co. Ltd. now owns 17,519 shares of the company's stock worth $221,000 after purchasing an additional 1,724 shares during the last quarter. 27.37% of the stock is owned by institutional investors and hedge funds.About HUTCHMED
(Get Rating)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
Further Reading
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Let Paychex Stock Work Hard For You
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 1,760,000 shares, a decrease of 18.9% from the August 31st total of 2,170,000 shares. Based on an average daily volume of 350,900 shares, the short-interest ratio is presently 5.0 days.
和黃醫藥(中國)有限公司(納斯達克：HCM-GET評級)在9月份看到空頭股數的銷售額大幅下降。截至9月15日，空頭股數共有176萬股，比8月31日的217萬股減少了18.9%。以日均成交量350,900股計算，目前短息比率為5.0天。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
HCM has been the topic of a number of recent research reports. StockNews.com upgraded shares of HUTCHMED from a "sell" rating to a "hold" rating in a research note on Monday, August 1st. The Goldman Sachs Group boosted their price objective on HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 9th.
HCM一直是最近一些研究報告的主題。在8月1日星期一的一份研究報告中，斯托克新聞網將和黃醫藥的股票評級從賣出上調為持有。8月9日，在週二的一份研究報告中，高盛夫婦將和黃醫藥的目標價從14.00美元上調至16.00美元，並給予該股“中性”評級。
HUTCHMED Stock Performance
和黃醫藥股票表現
HCM traded up $0.23 on Friday, reaching $8.86. The company's stock had a trading volume of 444,340 shares, compared to its average volume of 449,485. The stock has a 50 day moving average of $12.27 and a two-hundred day moving average of $13.25. HUTCHMED has a fifty-two week low of $8.37 and a fifty-two week high of $36.81.
上週五，HCM股價上漲0.23美元，達到8.86美元。該公司股票的成交量為444,340股，而其平均成交量為449,485股。該股的50日移動均線切入位為12.27美元，200日移動均線切入位為13.25美元。和黃醫藥目前的52周低點為8.37美元，52周高點為36.81美元。
Institutional Investors Weigh In On HUTCHMED
機構投資者看好和黃醫藥
About HUTCHMED
關於和黃醫藥
(Get Rating)
(獲取評級)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
和黃醫藥(中國)有限公司在香港和國際上發現、開發癌症和免疫疾病的靶向療法和免疫療法，並將其商業化。它在腫瘤學/免疫學和其他風險投資領域開展業務。該公司開發Savolitinib，一種治療非小細胞肺癌(NSCLC)、乳頭狀細胞癌和腎癌、結直腸癌(CRC)和胃癌(GC)的抑制劑；以及Fruquintinib，一種治療CRC、乳腺癌、GC、子宮內膜癌(EMC)、非小細胞肺癌、肝細胞癌以及胃腸道和實體腫瘤的抑制劑。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Let Paychex Stock Work Hard For You
- 免費獲取斯托克新聞網關於和黃醫藥的研究報告
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 利潤下降對CarMax價值主張的挑戰
- 讓Paychex股票為您努力工作
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
接受《和黃醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，即可通過MarketBeat.com的免費每日電子郵件時事通訊接收對和黃醫藥及相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧